What Is Hc3a? Definition and What Research Reports

Definition

Hc3a is a short alphanumeric label that appears in the published literature attached to two unrelated molecules, and which one is meant depends entirely on the field the paper sits in. In venom peptide research, Hc3a refers to a small disulfide-rich peptide purified from the venom of an Australian funnel-web spider, described as a "single knot" peptide because it contains one inhibitor cystine knot motif, and studied for its interaction with acid-sensing ion channel 1a (ASIC1a). In complement immunology and protein chemistry, the same string usually appears as hC3a s horthand for human complement C3a, the anaphylatoxin fragment released when complement component C3 is proteolytically cleaved during activation of the complement cascade. Neither usage describes a marketed drug or a supplement; both are laboratory research subjects.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment, or a specific compound. Nothing here describes a protocol, and no dose, schedule, or route of administration is suggested.

The two meanings side by side

Hc3a as a funnel-web spider venom peptide

Spider venoms are complex mixtures containing large numbers of small peptides, many of which fold around a compact cystine knot scaffold. Peptides of this type are of interest to ion channel pharmacologists because the knot makes them chemically stable and because individual peptides can be unusually selective for a single channel subtype. Hc3a belongs to this family and is described as a single knot peptide, meaning it carries one such knot rather than the two-domain architecture seen in some larger venom peptides.

Acid-sensing ion channel 1a

ASIC1a is a proton-gated cation channel that opens when extracellular pH falls and then rapidly enters a desensitised state. Because tissue acidosis accompanies ischaemia, inflammation, and other pathological conditions, ASIC1a has been a recurring subject of preclinical channel research, and venom peptides have historically been a major source of tools for probing it. A 2024 study in Biochemical Pharmacology reported that the funnel-web spider venom derived single knot peptide Hc3a modulated the desensitisation of ASIC1a (PMID 38552850). That is the specific pharmacological behaviour the study set out to characterise: not simple block or simple activation, but an effect on how the channel transitions out of the open state.

hC3a as human complement C3a

Complement C3 sits at the convergence point of the classical, lectin, and alternative complement pathways. When C3 is cleaved, the smaller fragment, C3a, is released as a 77-amino-acid anaphylatoxin that signals through the C3a receptor. C3a is therefore not a synthetic research peptide in origin; it is an endogenous human peptide generated on demand during immune activation. Because it drives inflammatory signalling, C3a has been a target for both detection chemistry and inhibition strategies, and the abbreviation hC3a is used in papers to distinguish the human sequence from C3a of other species.

Detection chemistry

Ligand-binding assays for C3aR require a labelled form of the ligand. Researchers described a europium-labelled synthetic C3a protein as a novel fluorescent probe for the human complement C3a receptor in a 2017 Bioconjugate Chemistry report (PMID 28562031). The relevance of that work to the glossary entry is definitional: it illustrates that C3a can be produced synthetically and chemically modified for laboratory use while retaining its identity as the receptor ligand under study.

Inhibition strategies

A separate line of work has asked whether C3a signalling can be intercepted. A 2020 paper in Biotechnology and Bioengineering reported effective inhibition of the C3a-mediated pro-inflammatory response by a human C3a-specific protein binder (PMID 32068245). In that framing, hC3a is the target rather than the tool, and the engineered binder is the experimental agent.

Post-translational modification and vascular permeability

An earlier report in Biological & Pharmaceutical Bulletin examined the effects of cholesterol-3-sulfate on the phosphorylation of human C3a in vitro and on the ability of hC3a to induce vascular permeability in rats (PMID 14993789). That study is a useful reference point for how hC3a is handled experimentally, since it combined an in vitro biochemical question about phosphorylation with an animal readout of C3a activity.

How the term is used in peptide research

Three practical points follow from the split meaning:

• Context disambiguates. A paper about proton-gated channels, venom fractionation, or cystine knot scaffolds is using Hc3a in the spider peptide sense; a paper about complement, anaphylatoxins, C3aR, or inflammation is using hC3a in the complement sense.
• Capitalisation is inconsistent. The complement usage is conventionally written with a lower-case leading "h" for human, but databases, search boxes, and informal writing routinely flatten this, which is why the two literatures collide under one string.
• Neither is an approved therapeutic. Both appear in the cited work as laboratory subjects. The venom peptide is characterised as a channel modulator in vitro (PMID 38552850), and human C3a appears as an endogenous ligand, a synthetic probe, or an inhibition target rather than as a candidate product (PMID 28562031, PMID 32068245).

What the published literature reports

Across the verified papers, the reported findings are narrow and mechanistic. The 2024 venom peptide study reported that Hc3a modulated ASIC1a desensitisation (PMID 38552850). The 2020 biotechnology study reported that a human C3a-specific protein binder effectively inhibited the C3a-mediated pro-inflammatory response (PMID 32068245). The 2017 bioconjugation study described a europium-labelled synthetic C3a as a fluorescent probe for the human C3a receptor (PMID 28562031), and the 2004 study examined cholesterol-3-sulfate effects on hC3a phosphorylation in vitro and on hC3a-induced vascular permeability in rats (PMID 14993789). No human efficacy trial appears among these sources.

Safety and Adverse Events: What Studies Report

The verified literature for this entry does not include human safety data, tolerability reporting, or adverse-event tables for either molecule. The venom peptide work described in the 2024 report is channel pharmacology rather than a safety study (PMID 38552850), and the complement papers are in vitro chemistry, cell-based inhibition work, and an animal permeability model (PMID 28562031, PMID 32068245, PMID 14993789). Any statement about human risk would therefore go beyond what these sources support, and this page makes none.

Scope of this entry

This is a reference definition. It does not describe preparation, handling, administration, sourcing, or any application in people, and it does not compare Hc3a with other peptides for any purpose. Readers tracing a specific claim are best served by reading the linked abstracts directly, since abstract-level scope is the boundary used throughout this page.

References

• The funnel-web spider venom derived single knot peptide Hc3a modulates acid-sensing ion channel 1a desensitisation (Biochemical Pharmacology, 2024)
• Effective inhibition of C3a-mediated pro-inflammatory response by a human C3a-specific protein binder (Biotechnology and Bioengineering, 2020)
• Europium-Labeled Synthetic C3a Protein as a Novel Fluorescent Probe for Human Complement C3a Receptor (Bioconjugate Chemistry, 2017)
• The effects of cholesterol-3-sulfate (CH-3S) on the phosphorylation of human C3a (hC3a) in vitro and on the ability of hC3a to induce vascular permeability in rats (Biological & Pharmaceutical Bulletin, 2004)